2014 access to medicine index: GSK topped the list four times

Source: bioprospecting 2014-11-19 in the world of more than 7 billion people, 2 billion people still can't afford drugs To this end, there are charities to assess and improve the status quo Each year, we will select 20 enterprises in the world committed to "making medicines available to all" according to their seven indicators of operation, policy, R & D, price, patent, development ability, donation and comprehensive weight The top 20 pharmaceutical companies that aim to measure efforts to improve drugs and healthcare in developing countries From the above list, it is surprising that the controversial and battered GSK in the past year should be at the top of the list For this reason, access to medicine index also analyzes this issue: on the one hand, as many as 18 of the 20 listed enterprises, like GSK, have violated market rules, suspected of bribery, corruption and even violated commercial laws such as the anti unfair competition law Therefore, with the advantages of GSK in research and development, pricing, patents and other aspects, the 3 billion penalty issued by the Chinese government for GSK has little impact on the index; on the other hand, some enterprises tend to conservatively disclose the validity period and expiration date of patents, which is very useful for pharmaceutical producers and generic manufacturers.